Program
Meloxicam
Also written as “HTX-011”, “N1539” and “Meloxicam tablet”.
Its studies are mostly in Pain, Postoperative · Osteoarthritis · Arthritis, Rheumatoid · Hernia, Inguinal · Pain, led by 16 companies.
Drug pageMeloxicam: every studyMany companies study it; this page follows only the 66 they lead. All 88 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 220 open or running | phase 4since Jul 4, 2014 | May 2, 2002 | none ahead |
| Heron Therapeutics | 161 open or running | phase 4since Oct 1, 2021 | Jun 9, 2015 | none ahead |
| Baudax Bioits history only | 70 open or running | phase 4since Mar 15, 2022 | Aug 31, 2015 | none ahead |
| Alkermesits history only | 30 open or running | phase 3since Sep 15, 2011 | Jul 23, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 12, 2010 | Jul 12, 2010 | none ahead |
| Eurofarma Laboratoriosits history only | 20 open or running | phase 3since Apr 24, 2012 | Apr 24, 2012 | none ahead |
| Grünenthalits history only | 20 open or running | phase 3since Sep 22, 2014 | Mar 18, 2013 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Feb 6, 2009 | Feb 6, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | no phasesince Nov 28, 2012 | Nov 28, 2012 | none ahead |
| Joint Stock Company "Farmak"its history only | 10 open or running | phase 1since Nov 15, 2021 | Nov 15, 2021 | none ahead |
| Pfizerits history only | 10 open or running | no phasesince Sep 6, 2011 | Sep 6, 2011 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 2since Jul 10, 2023 | Jul 10, 2023 | none ahead |
| Yangtze River Pharmaceutical Groupits history only | 10 open or running | phase 3since Mar 25, 2025 | Mar 25, 2025 | none ahead |
| Zodiac Produtos Farmaceuticosits history only | 10 open or running | phase 3since May 11, 2015 | May 11, 2015 | none ahead |
Also a collaborator on its studies: Eurotrials Brasil Consultores Cientificos Ltda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Heron Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2015First study: phase 2 study in AgnosiaFirst studyNCT02471898 · 71 enrolled · United States
- Jul 16, 2015Phase 2 study in Pain, PostoperativeNCT02504580 · 463 enrolled · United States
- Jan 3, 20172 phase 2 studies in Pain, PostoperativeNCT03011333, NCT03015532
- Jul 31, 2017Phase 3 study in Pain, PostoperativeNCT03237481 · 418 enrolled · United States, Belgium
- Sep 25, 2017Phase 3 study in Pain, PostoperativeNCT03295721 · 412 enrolled · United States
- Oct 1, 20182 phase 2 studies in Pain, PostoperativeNCT03695367, NCT03718039
- Apr 5, 2019Phase 3 study in AgnosiaNCT03907176 · 209 enrolled · United States
- Apr 17, 2019Phase 2 study in AgnosiaNCT03922048
- May 9, 2019Phase 2 study in Pain, PostoperativeNCT03955211 · 25 enrolled · United States
- Jun 3, 2019Phase 3 study in AgnosiaNCT03974932 · 116 enrolled · United States
- May 27, 2021Phase 2 study in Pain, PostoperativeNCT04911062 · 32 enrolled · United States
- Oct 1, 2021Phase 4 study in AgnosiaNCT05109312 · 90 enrolled · United States
- Oct 25, 20232 phase 4 studies in Pain, PostoperativeNCT06109428, NCT06109415
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Celecoxibrule | Viatris | phase 4 | 78 |
| Etoricoxibrule | Organon | phase 4 | 35 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 16 Heron Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06109428Pain, Postoperative · United States | 4 | Completed | Mar 29, 2022 | 37 |
| NCT06109415Pain, Postoperative · United States | 4 | Completed | Jul 18, 2022 | 30 |
| NCT05109312Agnosia · United States | 4 | Active, not recruiting | Jun 2024 | 90 |
| NCT04911062Pain, Postoperative · United States | 2 | Completed | Jul 29, 2022 | 32 |
| NCT03974932Agnosia · United States | 3 | Completed | Dec 7, 2020 | 116 |
| NCT03955211Pain, Postoperative · United States | 2 | Completed | Dec 3, 2021 | 25 |
| NCT03922048Agnosia | 2 | Withdrawn | Nov 2025 | 0 |
| NCT03907176Agnosia · United States | 3 | Completed | Oct 25, 2021 | 209 |
| NCT03718039Pain, Postoperative · United States | 2 | Completed | Jan 31, 2019 | 78 |
| NCT03695367Pain, Postoperative · United States | 2 | Completed | Nov 20, 2018 | 63 |
| NCT03295721Pain, Postoperative · United States | 3 | Completed | Jan 8, 2018 | 412 |
| NCT03237481Pain, Postoperative · United States, Belgium | 3 | Completed | Dec 22, 2017 | 418 |
| NCT03015532Pain, Postoperative · United States | 2 | Completed | Apr 20, 2018 | 285 |
| NCT03011333Pain, Postoperative · United States | 2 | Completed | Feb 1, 2018 | 243 |
| NCT02504580Pain, Postoperative · United States | 2 | Completed | Mar 2017 | 463 |
| NCT02471898Agnosia · United States | 2 | Completed | Sep 2015 | 71 |
How it is read
Names in the registry
- “HTX-011”, 20 entries
- “N1539”, 18 entries
- “Meloxicam”, 12 entries
- “Meloxicam tablet”, 3 entries
- “Meloxicam 15 mg Tablets”, 2 entries
Conditions, from the studies’ own filings
- Pain, Postoperative, 21 studies
- Osteoarthritis, 6 studies
- Arthritis, Rheumatoid, 3 studies
- Hernia, Inguinal, 2 studies
- Pain, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.